Financhill
Sell
23

STAA Quote, Financials, Valuation and Earnings

Last price:
$18.29
Seasonality move :
13.75%
Day range:
$17.05 - $17.97
52-week range:
$13.50 - $52.68
Dividend yield:
0%
P/E ratio:
49.73x
P/S ratio:
2.77x
P/B ratio:
2.19x
Volume:
783.8K
Avg. volume:
1.4M
1-year change:
-53.3%
Market cap:
$868.9M
Revenue:
$313.9M
EPS (TTM):
-$0.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
STAA
Staar Surgical
$77.5M -$0.01 -47.87% -731.74% $18.67
COO
The Cooper Companies
$980.9M $0.91 5.65% 111.18% $107.29
KIDS
OrthoPediatrics
$51.2M -$0.26 16.06% -22.55% $39.00
LUCY
Innovative Eyewear
$1M -$1.16 62.4% -78.2% --
NXGL
NexGel
$3M -$0.13 176.53% -35% --
PDEX
Pro-Dex
$13.8M $0.38 23.84% 147.37% $54.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
STAA
Staar Surgical
$17.62 $18.67 $868.9M 49.73x $0.00 0% 2.77x
COO
The Cooper Companies
$79.91 $107.29 $16B 38.79x $0.01 0% 4.08x
KIDS
OrthoPediatrics
$24.96 $39.00 $606.2M -- $0.00 0% 2.81x
LUCY
Innovative Eyewear
$3.69 -- $9M -- $0.00 0% 2.41x
NXGL
NexGel
$2.89 -- $19.6M -- $0.00 0% 2.63x
PDEX
Pro-Dex
$48.89 $54.00 $159.4M 24.45x $0.00 0% 2.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
STAA
Staar Surgical
-- 1.099 -- 4.41x
COO
The Cooper Companies
23.79% 1.808 13.14% 0.82x
KIDS
OrthoPediatrics
17.1% 0.481 13.02% 3.27x
LUCY
Innovative Eyewear
-- 12.933 -- 14.63x
NXGL
NexGel
18.36% 0.186 5.91% 0.64x
PDEX
Pro-Dex
33.99% 3.333 10.75% 1.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
STAA
Staar Surgical
$31.6M -$27.9M -5.02% -5.02% -57.02% -$5.1M
COO
The Cooper Companies
$660.2M $182M 3.93% 5.24% 18.59% $101.2M
KIDS
OrthoPediatrics
$35.6M -$8.6M -9.36% -10.25% -10.07% -$3.7M
LUCY
Innovative Eyewear
$59.3K -$1.8M -113.55% -113.55% -678.5% -$1.5M
NXGL
NexGel
$1.3M -$788K -59.05% -67.5% -24.97% -$1.2M
PDEX
Pro-Dex
$5.1M $2.7M 15.21% 21.59% 16.61% -$4.7M

Staar Surgical vs. Competitors

  • Which has Higher Returns STAA or COO?

    The Cooper Companies has a net margin of -69.92% compared to Staar Surgical's net margin of 10.81%. Staar Surgical's return on equity of -5.02% beat The Cooper Companies's return on equity of 5.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    STAA
    Staar Surgical
    64.65% -$0.69 $397.3M
    COO
    The Cooper Companies
    68.44% $0.52 $10.7B
  • What do Analysts Say About STAA or COO?

    Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand The Cooper Companies has an analysts' consensus of $107.29 which suggests that it could grow by 34.27%. Given that The Cooper Companies has higher upside potential than Staar Surgical, analysts believe The Cooper Companies is more attractive than Staar Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    STAA
    Staar Surgical
    3 9 1
    COO
    The Cooper Companies
    9 7 0
  • Is STAA or COO More Risky?

    Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison The Cooper Companies has a beta of 1.022, suggesting its more volatile than the S&P 500 by 2.176%.

  • Which is a Better Dividend Stock STAA or COO?

    Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Staar Surgical pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STAA or COO?

    Staar Surgical quarterly revenues are $49M, which are smaller than The Cooper Companies quarterly revenues of $964.7M. Staar Surgical's net income of -$34.2M is lower than The Cooper Companies's net income of $104.3M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while The Cooper Companies's PE ratio is 38.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 4.08x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STAA
    Staar Surgical
    2.77x 49.73x $49M -$34.2M
    COO
    The Cooper Companies
    4.08x 38.79x $964.7M $104.3M
  • Which has Higher Returns STAA or KIDS?

    OrthoPediatrics has a net margin of -69.92% compared to Staar Surgical's net margin of -30.51%. Staar Surgical's return on equity of -5.02% beat OrthoPediatrics's return on equity of -10.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    STAA
    Staar Surgical
    64.65% -$0.69 $397.3M
    KIDS
    OrthoPediatrics
    67.53% -$0.69 $427.7M
  • What do Analysts Say About STAA or KIDS?

    Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand OrthoPediatrics has an analysts' consensus of $39.00 which suggests that it could grow by 56.25%. Given that OrthoPediatrics has higher upside potential than Staar Surgical, analysts believe OrthoPediatrics is more attractive than Staar Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    STAA
    Staar Surgical
    3 9 1
    KIDS
    OrthoPediatrics
    2 1 0
  • Is STAA or KIDS More Risky?

    Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.767%.

  • Which is a Better Dividend Stock STAA or KIDS?

    Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STAA or KIDS?

    Staar Surgical quarterly revenues are $49M, which are smaller than OrthoPediatrics quarterly revenues of $52.7M. Staar Surgical's net income of -$34.2M is lower than OrthoPediatrics's net income of -$16.1M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.81x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STAA
    Staar Surgical
    2.77x 49.73x $49M -$34.2M
    KIDS
    OrthoPediatrics
    2.81x -- $52.7M -$16.1M
  • Which has Higher Returns STAA or LUCY?

    Innovative Eyewear has a net margin of -69.92% compared to Staar Surgical's net margin of -678.5%. Staar Surgical's return on equity of -5.02% beat Innovative Eyewear's return on equity of -113.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    STAA
    Staar Surgical
    64.65% -$0.69 $397.3M
    LUCY
    Innovative Eyewear
    23.4% -$0.99 $10.9M
  • What do Analysts Say About STAA or LUCY?

    Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand Innovative Eyewear has an analysts' consensus of -- which suggests that it could grow by 279.4%. Given that Innovative Eyewear has higher upside potential than Staar Surgical, analysts believe Innovative Eyewear is more attractive than Staar Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    STAA
    Staar Surgical
    3 9 1
    LUCY
    Innovative Eyewear
    0 0 0
  • Is STAA or LUCY More Risky?

    Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock STAA or LUCY?

    Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STAA or LUCY?

    Staar Surgical quarterly revenues are $49M, which are larger than Innovative Eyewear quarterly revenues of $253.6K. Staar Surgical's net income of -$34.2M is lower than Innovative Eyewear's net income of -$1.7M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.41x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STAA
    Staar Surgical
    2.77x 49.73x $49M -$34.2M
    LUCY
    Innovative Eyewear
    2.41x -- $253.6K -$1.7M
  • Which has Higher Returns STAA or NXGL?

    NexGel has a net margin of -69.92% compared to Staar Surgical's net margin of -23.57%. Staar Surgical's return on equity of -5.02% beat NexGel's return on equity of -67.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    STAA
    Staar Surgical
    64.65% -$0.69 $397.3M
    NXGL
    NexGel
    43.61% -$0.11 $6M
  • What do Analysts Say About STAA or NXGL?

    Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand NexGel has an analysts' consensus of -- which suggests that it could grow by 107.61%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    STAA
    Staar Surgical
    3 9 1
    NXGL
    NexGel
    0 0 0
  • Is STAA or NXGL More Risky?

    Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock STAA or NXGL?

    Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STAA or NXGL?

    Staar Surgical quarterly revenues are $49M, which are larger than NexGel quarterly revenues of $2.9M. Staar Surgical's net income of -$34.2M is lower than NexGel's net income of -$693K. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.63x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STAA
    Staar Surgical
    2.77x 49.73x $49M -$34.2M
    NXGL
    NexGel
    2.63x -- $2.9M -$693K
  • Which has Higher Returns STAA or PDEX?

    Pro-Dex has a net margin of -69.92% compared to Staar Surgical's net margin of 12.15%. Staar Surgical's return on equity of -5.02% beat Pro-Dex's return on equity of 21.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    STAA
    Staar Surgical
    64.65% -$0.69 $397.3M
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
  • What do Analysts Say About STAA or PDEX?

    Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 10.45%. Given that Pro-Dex has higher upside potential than Staar Surgical, analysts believe Pro-Dex is more attractive than Staar Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    STAA
    Staar Surgical
    3 9 1
    PDEX
    Pro-Dex
    1 0 0
  • Is STAA or PDEX More Risky?

    Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison Pro-Dex has a beta of 0.682, suggesting its less volatile than the S&P 500 by 31.755%.

  • Which is a Better Dividend Stock STAA or PDEX?

    Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STAA or PDEX?

    Staar Surgical quarterly revenues are $49M, which are larger than Pro-Dex quarterly revenues of $16.8M. Staar Surgical's net income of -$34.2M is lower than Pro-Dex's net income of $2M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Pro-Dex's PE ratio is 24.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.73x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STAA
    Staar Surgical
    2.77x 49.73x $49M -$34.2M
    PDEX
    Pro-Dex
    2.73x 24.45x $16.8M $2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock